Catalyst Pharmaceuticals reports Q4 adjusted EPS 56c, consensus 26c

Reports Q4 revenue $110.6M, consensus $105.92M. “In 2023, Catalyst delivered exceptional financial performance demonstrated by robust revenue growth, exceeding our full-year guidance. Our confidence for continued growth is strengthened by the outstanding execution of our strategic initiatives, expansion of our product portfolio, and a growing commercial presence in the U.S. neuroscience market,” stated Richard J. Daly, CEO of Catalyst. “As we enter this year with compelling momentum, our commitment to execution and advancement of our initiatives, with a concentration on orphan CNS and other strategic adjacencies, remains resolute. With an imminent U.S. commercial launch for AGAMREE, we are well poised to propel further growth. We eagerly anticipate making this innovative therapy available to eligible Duchenne muscular dystrophy patients. Coupled with our accomplishments, substantial cash reserves, and prudent financial management, we aim to further fuel our growth through strategic avenues that will deliver further value while upholding our steadfast commitment to serving our patient communities.”